Stocks · News reference
Lakewood-Amedex Biotherapeutics shares are trading higher after the company announced Minimum Inhibitory Concentration data from recent clinical isolates for its lead clinical candidate, Nu-3.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lakewood-Amedex Biotherapeutics shares are trading higher after the company announced preclinical data in UTI and pulmonary infection indications in animal models treated with Bisphosphocin compounds.
Lakewood-Amedex Says Nu-8 Shows Up To 97% Inhibition Of E. Coli Growth In Rodent Urinary Tract Infection Model